Form 4: ADMA Biologics CEO Adam Grossman Reports Stock Sales and Option Exercise
SEC Form 4
Adam Grossman, CEO of ADMA Biologics, reports the sale of common stock and exercise of options under a pre-arranged trading plan.
Summary
- On March 19, 2025, Adam Grossman, the President and CEO of ADMA Biologics, executed transactions involving the company's common stock.
- Grossman exercised options to acquire 15,000 shares at a price of $5.40 per share.
- Simultaneously, Grossman sold 15,000 shares at $18.92 per share and an additional 6,000 shares at $18.92 per share.
- These transactions were conducted under a Rule 10b5-1 trading plan established on December 5, 2024.
- Following these transactions, Grossman directly owns 2,061,850 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
- Additionally, Grossman holds options for 855,950 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, but the sale of shares could be perceived negatively by some investors.
Positives
- The transactions were executed under a pre-existing Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Negatives
- The sale of shares by the CEO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.
Risks
- Executive stock sales, even under a 10b5-1 plan, can sometimes create short-term price volatility.
Industry Context
Executive stock transactions are common in publicly traded companies, particularly in the biotechnology sector. Investors often monitor these transactions for insights into management's confidence in the company's future prospects. Rule 10b5-1 plans are frequently used to schedule these transactions in advance to avoid any appearance of impropriety.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include stock options and restricted stock units (RSUs) to align management's interests with those of shareholders.
- The vesting schedules for RSUs and stock options, such as the quarterly vesting over four years described in the document, are typical in the industry.
- The use of Rule 10b5-1 trading plans is a standard practice among executives to manage their stock holdings in a compliant manner.
Stakeholder Impact
- The stock sale could have a minor short-term impact on shareholders due to potential price fluctuations.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-03-07 | 75,000 unvested RSUs granted that will vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2023-03-06 | 286,848 unvested RSUs granted that will vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2024-02-26 | 418,296 unvested RSUs granted that will vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2024-02-26 | Option was granted and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028. |
| 2024-12-05 | Date of Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC. |
| 2025-02-19 | 252,022 unvested RSUs granted that will vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2025-02-26 | 217,737 shares of common stock underlying the option vesting on February 26, 2025, the one-year anniversary of the date of grant. |
| 2025-03-19 | Date of stock sale and option exercise. |
| 2028-02-26 | Option becomes fully vested. |
| 2034-02-26 | Expiration date of the option. |
Keywords
ADMA Biologics, Adam Grossman, stock sale, Form 4, Rule 10b5-1, insider trading, options, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.